Save up -80% on Selexipag

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Uptravi



* price without discount in nearest pharmacy. Price may vary.

Claim your free Selexipag discount card

We offer free Selexipag coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Selexipag every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Selexipag volume of distribution

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Selexipag

Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.

Selexipag mechanism of action

Selexipag is a selective prostacyclin (IP, also called PGI2) receptor agonist. The key features of pulmonary arterial hypertension include a decrease in prostacyclin and prostacyclin synthase (enzyme that helps produce prostacyclin) in the lung. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects; therefore, there is strong rationale for treatment with IP receptor agonists. Selexipag is chemically distinct as it is not PGI2 or a PGI2 analogue and has high selectivity for the IP receptor. It is metabolized by carboxylesterase 1 to yield an active metabolite (ACT-333679) that is approximately 37 times more potent than selexipag. Both selexipag and its metabolite are selective for the IP receptor over other prostanoid receptors.

Dosage forms of Selexipag

Uptravi1600mcg60 tablets$16,784
Uptravi200mcg and 800mcg1 titration pack (200 tablets)$25,178
Prescription Generics


International Brands




Actelion Pharmaceuticals US, Inc.

CAS number






Affected organisms

Humans and other mammals

Indication of Selexipag

Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

Toxicity of Selexipag

A 40-70% increase in exposure was observed in subjects with severe renal impairment.

RX24 Drugs Disclaimer: before buying a Selexipag on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Selexipag now!